Healthcare, Pharma & Life Sciences

BOSTON – October 30, 2026 -- Medicilon presented Revolution Medicines, Inc. with its "Excellence in Client Partnership Award" after more than three years of joint work on pan-KRAS drug discovery, following the U.S. FDA's August 2026 approval of the NDA for Daraxonrasib in metastatic pancreatic cancer.

Dr. Yang Liu, Director of Medicinal Chemistry at Revolution Medicines, and Senior Scientist Dr. Kristof Pota received the award during a visit to Medicilon's Nanhui R&D Center. Dr. Maosheng Duan, President of Medicilon's Drug Discovery and Pharmaceutical Research Divisions, and Dr. Jian Wang, Vice President, hosted the delegation.

Marburg – October 30, 2026 -- More than 180 participants attended the first Menopause Day at University Hospital Marburg (UKGM), which put menopause on the agenda of workplace health management under the motto "Menopause at Work - Inform, Connect, Support."

Women's Health Center runs hybrid format with two lecture blocks

The Women's Health Center at UKGM Marburg organized the event. Attendees could join on site or online. Individual medical consultations followed the lectures, so participants could raise personal health questions confidentially.

PD Dr. Gamal-André Banat opened the day on behalf of the UKGM management. He described the topic as important for employee health and well-being and praised the initiative as modern, employee-focused health promotion.

TAIPEI – October 30, 2026 -- HanchorBio (TWSE: 7827) has received Taiwan Food and Drug Administration approval for the Investigational New Drug application for HCB303, its trispecific TIGIT-Fc ligand-trap fusion protein, following U.S. FDA clearance. The approval was granted to its wholly owned subsidiary, FBD Biologics Limited, and gives the asset regulatory authorization for clinical investigation in two jurisdictions.

TFDA used a 15-day accelerated pathway for multinational trials

HCB303 cleared through Taiwan's accelerated review route for multinational, multicenter clinical trials, which provides a 15-day review for eligible applications. TFDA has also simplified submission requirements for qualifying first-in-human studies. Under applicable conditions, sponsors no longer need to submit institutional review board approval letters from foreign participating hospitals.

NEW YORK – October 30, 2026 -- The Galien Foundation marked the 20th anniversary of the Prix Galien USA Awards at the American Museum of Natural History, adding a new Patient First Award and presenting international honors alongside the U.S. prizes.

Eight U.S. categories judged by a 51-member panel

Winners were selected by the Prix Galien USA Committees, which comprise 25 committee members, 11 subcommittee members and 15 advisory board members. Three Nobel Laureates sit on the panels. The U.S. awards covered eight categories: Best Biotechnology Product, Best Pharmaceutical Product, Best Product for Rare/Orphan Diseases, Best Medical Technology, Best Digital Health Solution, Incubators, Accelerators and Equity, Prix Galien EcoHealth, and Best Startup.

North Brunswick, N.J. – October 30, 2026 -- All five antibody-deficient mice treated with Lactiga's LCTG-001 survived influenza infection, compared with two of five in the control group, according to a peer-reviewed preclinical study conducted by McMaster University scientists in collaboration with Lactiga US, Inc.

The research was published in Science Advances on October 14, 2026. LCTG-001 is a nasal antibody treatment made from secretory immunoglobulin A (sIgA) purified from donated human breast milk. Lactiga is developing it for patients with common variable immunodeficiency (CVID) who keep getting respiratory infections despite existing therapies.

Cambridge – October 30, 2026 -- LabCentral, C10 Labs and Innovation Centre Denmark Boston will host Entangled 2026 on November 19 at The Platform in Kendall Square, convening more than 250 leaders from biotech, deep tech, investment, academia and government, including a delegation of about 50 from Denmark.

Summit targets AI and quantum computing in drug discovery

The one-day event is built around the question "What makes the next breakthrough possible?" Organizers say advances in artificial intelligence and quantum computing, combined with cross-sector collaboration, can open new routes for scientific innovation. The program will concentrate on the expertise, partnerships and resources needed to turn those technologies into scientific progress.

CAMBRIDGE, Mass. – October 30, 2026 -- Whitehead Institute researchers have profiled more than 600,000 cells from the transparent fish Danionella cerebrum to build the first comprehensive whole-body single-cell atlas of an adult vertebrate, according to a study published in Science on October 29.

Atlas links gene activity to cell location across the whole animal

The map is a single-cell transcriptome atlas, a record of which genes are active in which cell. The team used single-cell RNA sequencing on cells collected from the brain, spinal cord, eyes, internal organs, fins, head and trunk. It paired those data with spatial methods that place cell types and gene activity patterns in their tissue locations. The atlas captures even exceptionally rare cell populations.

The data give researchers a baseline for testing how injury, aging, drugs or other changes affect cells across the whole animal.

Warren – October 30, 2026 -- PTC Therapeutics (NASDAQ: PTCT) reported third-quarter 2026 total revenue of $358 million and raised its full-year product revenue guidance to $960 million to $990 million, up from $850 million to $950 million. Total revenue guidance for 2026 now stands at $1.29 billion to $1.32 billion.

Product revenue more than doubles on Sephience launch

Net product revenue across the commercial portfolio reached $275.9 million, against $131.0 million in the third quarter of 2025. Net product and royalty revenue combined totaled $357.6 million, compared with $201.7 million a year earlier.

Sephience (sepiapterin) generated $181.9 million, up 20% from the second quarter. US sales were $145 million and ex-US sales $37 million. More than 2,000 patients were on therapy worldwide as of September 30. CEO Matthew Klein said the launch has been a success by all measures and that PTC is on track to reach cash flow breakeven this year.

CHICAGO – October 30, 2026 -- The American Lung Association Research Institute has invested $21 million in research and related scientific activities this year, bringing its total direct research funding over the past decade to $193 million.

More than $11 million goes to 120 research projects

The $21 million covers direct research funding of more than $11 million for 120 projects, plus related scientific activities. The projects run through three programs: the Awards and Grants Program, the Airways Clinical Research Centers Network and the Accelerator Program. The $193 million ten-year figure also includes the infrastructure and scientific support needed to advance research.

WINDHAM, N.H. – October 30, 2026 -- Ambulatory surgery center (ASC) volumes are projected to grow 24% over the next decade, while national workforce projections point to clinician shortages in 2027 across specialties that drive ASC case volume. Medicus Healthcare Solutions, a locum tenens and healthcare workforce company, released a report compiling industry research, national data and its own proprietary data on the trend.

Outpatient settings now handle more than 80% of surgeries

The report, titled "Ambulatory Surgery Centers: Market Growth, Workforce Pressures, and Operational Demands," finds that more than 80% of surgeries are now performed in an outpatient setting. About 90% of ASCs have some degree of physician ownership.

Maryland, Georgia, Idaho and Arizona lead on ASC density

These four states have the highest number of ASCs per 100,000 residents, according to the report.